Trial · NCT03136445
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Proportion of Patients Who Die or Have Bleeding of WHO Grade 2 or Above by WHO Criteria During the First 30 Days From the First Dose of Trial Treatment, or Planned First Dose for Those Participants Who do Not Receive Treatment. | The first 30 days from first dose of trial treatment | Participants with primary outcome data reported | percentage of participants | NUMBER |
| SECONDARY | Mean (SD) Percentage of Days With WHO Grade 2 Bleeding or Above, Per Participant. | The first 30 days from first dose of trial treatment . | Participants with primary outcome data reported | percentage of days | MEAN |
| SECONDARY | Time to First Episode of Bleeding of WHO Grade 2 or Greater up to Study Day 30. | The first 30 days from first dose of trial treatment. | Participants with primary outcome data reported | Lower quartile for number of days | MEDIAN |
| SECONDARY | Highest Grade of Bleeding a Patient Experiences up to Study Day 30. | The first 30 days from first dose of trial treatment. | Data is only presented for participants who experienced at least one bleed | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Platelet Transfusions Per Patient up to Study Day 30. | The first 30 days from first dose of trial treatment. | Participants with primary outcome data reported | platelet units | MEDIAN |
| SECONDARY | Number of Red Cell Transfusions Per Patient up to Study Day 30. | The first 30 days from first dose of trial treatment. | Participants with primary outcome data reported | Red cell units | MEDIAN |
| SECONDARY | Proportion of Patients Surviving at Least 30 Days Without a Platelet Transfusion. | The first 30 days from first dose of trial treatment. | Participants with primary outcome data reported | proportion | NUMBER |
| SECONDARY | Proportion of Patients Surviving at Least 30 Days Without a Red Cell Transfusion. | The first 30 days from first dose of trial treatment. | Participants with primary outcome data reported | proportion | NUMBER |
| SECONDARY | Number of Participants With a Thrombotic Event From First Administration of Trial Treatment up to and Including 120 Days After the First Dose of Trial Treatment is Received (N) | Up to and including 120 days from the first administration of investigational medicinal product (IMP). | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Patients Developing Veno-occlusive Disease (VOD; Sinusoidal Obstructive Syndrome, SOS) Within 60 Days of First Administration of Trial Treatment. | Up to and including 60 days from the first administration of IMP. | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | All-cause Mortality During the First 30 Days and 120 Days After the First Dose of Trial Treatment is Administered. | Up to and including 120 days from the first administration of IMP. | 4 Participants were missing mortality data and so weren't analysd | proportion | NUMBER |
| SECONDARY | Death Due to Thrombosis During the First 120 Days After the First Dose of Trial Treatment is Administered. | Up to and including 120 days from the first administration of IMP. | percent | NUMBER | |
| SECONDARY | Death Due to Bleeding During the First 30 Days After the First Dose of Trial Treatment is Administered. | Up to and including 30 days from the first administration of IMP. | percent | NUMBER | |
| SECONDARY | Number of Serious Adverse Events (SAE) From First Administration of Trial Treatment Until 60 Days After the First Dose of Trial Treatment is Administered. | Up to and including 60 days from the first administration of IMP. | Serious adverse events | NUMBER | |
| OTHER_PRE_SPECIFIED | Proportion of Days With Thrombocytopenia (≤10x10⁹/L, ≤30x10⁹L, ≤50x10⁹/L). | Measured during first 30 days from first dose of IMP. | Days platelet count count was recorded (so risk of thrombocytopenia could be detected) | Days with thrombocytopenia | MEAN |
| OTHER_PRE_SPECIFIED | Reasons for Platelet Transfusions. | Measured during first 30 days from first dose of IMP. | Participants with at least one platelet transfusion | Platelet transfusions | NUMBER |
| OTHER_PRE_SPECIFIED | Reasons for Red Cell Transfusions. | Measured during first 30 days from first dose of IMP. | Participants with at least one red cell transfusion | Red cell transfusions | NUMBER |
| OTHER_PRE_SPECIFIED | Proportion of Days With Fever | Measured during first 30 days from first dose of IMP. | Participants with fever data reported | Days | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03136445/outcomes